Loading...
XKRX087010
Market cap1.40bUSD
Dec 24, Last price  
99,000.00KRW
1D
4.76%
1Q
106.68%
Jan 2017
405.75%
IPO
83.33%
Name

Peptron Inc

Chart & Performance

D1W1MN
XKRX:087010 chart
P/E
—
P/S
611.05
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
3.89%
Rev. gr., 5y
-2.85%
Revenues
3.34b
-42.52%
3,100,534,0003,103,476,7202,483,532,2202,812,386,7713,130,705,2953,215,383,9943,861,733,2101,801,118,5273,120,697,6946,624,511,9635,813,995,5373,341,893,572
Net income
-15.92b
L+5.70%
-2,559,474,000-2,059,418,400-3,046,281,250-2,730,419,563-3,190,975,867-4,426,816,681-3,725,911,350-17,717,554,794-18,381,916,319-15,041,985,237-15,062,790,476-15,921,881,877
CFO
-10.97b
L-6.37%
-958,521,000-1,319,803,030-2,856,433,460-2,355,852,688-2,729,800,627-5,625,535,862-4,180,119,815-9,599,502,080-13,550,207,785-10,614,800,228-11,719,975,876-10,973,481,430
Dividend
Mar 15, 20220.285 KRW/sh
Earnings
Mar 18, 2025

Profile

Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.
URL
http://www.peptron.co.kr/
IPO date
Jul 22, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,341,894
-42.52%
5,813,996
-12.24%
6,624,512
112.28%
Cost of revenue
16,588,088
19,446,795
21,146,571
Unusual Expense (Income)
NOPBT
(13,246,194)
(13,632,800)
(14,522,059)
NOPBT Margin
Operating Taxes
(18,937)
(4,206)
(241,754)
Tax Rate
NOPAT
(13,227,257)
(13,628,593)
(14,280,305)
Net income
(15,921,882)
5.70%
(15,062,790)
0.14%
(15,041,985)
-18.17%
Dividends
Dividend yield
Proceeds from repurchase of equity
(891,084)
2,009
BB yield
0.11%
0.00%
Debt
Debt current
4,606,890
9,143,948
3,054,646
Long-term debt
4,610,084
163,782
6,101,261
Deferred revenue
8
52,261
Other long-term liabilities
3,404,920
2,683,445
2,789,142
Net debt
202,409
(11,508,617)
(27,600,345)
Cash flow
Cash from operating activities
(10,973,481)
(11,719,976)
(10,614,800)
CAPEX
(731,086)
(1,715,388)
(774,771)
Cash from investing activities
11,038,842
12,073,799
(25,877,384)
Cash from financing activities
(852,535)
(47,810)
(26,904,014)
FCF
(7,389,375)
(20,712,221)
(11,593,137)
Balance
Cash
4,982,736
17,242,834
30,235,795
Long term investments
4,031,830
3,573,513
6,520,456
Excess cash
8,847,471
20,525,647
36,425,026
Stockholders' equity
21,270,100
37,639,232
(70,257,204)
Invested Capital
39,817,449
44,493,009
144,485,043
ROIC
ROCE
EV
Common stock shares outstanding
20,581
20,627
20,627
Price
40,250.00
426.14%
7,650.00
-31.08%
11,100.00
 
Market cap
828,396,359
424.98%
157,795,425
-31.08%
228,958,068
 
EV
828,598,768
146,286,809
201,357,724
EBITDA
(10,351,879)
(8,578,396)
(11,012,403)
EV/EBITDA
Interest
396,039
279,660
36,840
Interest/NOPBT